Custom Criteria for
BlueCross Blue Shield of Rhode Island Commercial

XALKORI (crizotinib)

## GPI CODING:

215340150001**

## DESCRIPTION:

Xalkori is a kinase inhibitor indicated for the treatment of patients with locally advanced or metastatic non-small cell lung cancer that is anaplastic lymphoma kinase (ALK)-positive as detected by an FDA-approved test.

## APPROVAL DURATION:

Approval duration: 1 year
Quantity limit: 2 tablets per day (250 mg/tablet or 200 mg/tablet)

## CRITERIA FOR XALKORI

I. Patient has a diagnosis of non-small cell lung cancer **OR**
II. Off label uses for oncology drugs if considered medically acceptable in one or more of the following compendia (i.e., Micromedex DrugDex, AHFS, Clinical Pharmacology, and NCCN.)) A use is identified by a compendium as medically accepted if the:
    A. Indication is a Category 1 or 2A in NCCN,
    B. Indication is a Class I, Class IIa or Class IIb in DrugDex,
    C. Narrative text in AHFS or Clinical Pharmacology is supportive; or
    D. The use is supported by clinical research in 2 or more peer-reviewed medical journals

**AND**

III. Patient has locally advanced or metastatic disease **AND**
IV. Genetic testing was performed for the ALK mutation **AND**
V. The lung cancer is ALK positive **AND**
VI. The requested quantity is no more than 2 tablets per day